150 related articles for article (PubMed ID: 22302256)
1. Comparison of rates of reported adverse events associated with i.v. iron products in the United States.
Bailie GR
Am J Health Syst Pharm; 2012 Feb; 69(4):310-20. PubMed ID: 22302256
[TBL] [Abstract][Full Text] [Related]
2. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America.
Bailie GR; Hörl WH; Verhoef JJ
Arzneimittelforschung; 2011; 61(5):267-75. PubMed ID: 21755809
[TBL] [Abstract][Full Text] [Related]
3. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
Faich G; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
[TBL] [Abstract][Full Text] [Related]
4. Update on adverse drug events associated with parenteral iron.
Chertow GM; Mason PD; Vaage-Nilsen O; Ahlmén J
Nephrol Dial Transplant; 2006 Feb; 21(2):378-82. PubMed ID: 16286429
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity reactions and deaths associated with intravenous iron preparations.
Bailie GR; Clark JA; Lane CE; Lane PL
Nephrol Dial Transplant; 2005 Jul; 20(7):1443-9. PubMed ID: 15855210
[TBL] [Abstract][Full Text] [Related]
6. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.
Wang C; Graham DJ; Kane RC; Xie D; Wernecke M; Levenson M; MaCurdy TE; Houstoun M; Ryan Q; Wong S; Mott K; Sheu TC; Limb S; Worrall C; Kelman JA; Reichman ME
JAMA; 2015 Nov; 314(19):2062-8. PubMed ID: 26575062
[TBL] [Abstract][Full Text] [Related]
7. Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System.
Trumbo H; Kaluza K; Numan S; Goodnough LT
Drug Saf; 2021 Jan; 44(1):107-119. PubMed ID: 33237523
[TBL] [Abstract][Full Text] [Related]
8. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
[TBL] [Abstract][Full Text] [Related]
9. Differences in the reporting rates of serious allergic adverse events from intravenous iron by country and population.
Bailie GR; Verhoef JJ
Clin Adv Hematol Oncol; 2012 Feb; 10(2):101-8. PubMed ID: 22402351
[TBL] [Abstract][Full Text] [Related]
10. Use of parenteral iron products and serious anaphylactic-type reactions.
Wysowski DK; Swartz L; Borders-Hemphill BV; Goulding MR; Dormitzer C
Am J Hematol; 2010 Sep; 85(9):650-4. PubMed ID: 20661919
[TBL] [Abstract][Full Text] [Related]
11. On the relative safety of parenteral iron formulations.
Chertow GM; Mason PD; Vaage-Nilsen O; Ahlmén J
Nephrol Dial Transplant; 2004 Jun; 19(6):1571-5. PubMed ID: 15150356
[TBL] [Abstract][Full Text] [Related]
12. Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System.
Min J; Osborne V; Kowalski A; Prosperi M
Drug Saf; 2018 Mar; 41(3):313-320. PubMed ID: 29098610
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
Coté TR; Mohan AK; Polder JA; Walton MK; Braun MM
J Am Acad Dermatol; 2005 Sep; 53(3):407-15. PubMed ID: 16112345
[TBL] [Abstract][Full Text] [Related]
14. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
Sane R; Baribeault D; Rosenberg CL
Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity from intravenous iron products.
Bircher AJ; Auerbach M
Immunol Allergy Clin North Am; 2014 Aug; 34(3):707-23, x-xi. PubMed ID: 25017687
[TBL] [Abstract][Full Text] [Related]
16. Comparative rates of adverse events with different formulations of intravenous iron.
Okam MM; Mandell E; Hevelone N; Wentz R; Ross A; Abel GA
Am J Hematol; 2012 Nov; 87(11):E123-4. PubMed ID: 22965928
[TBL] [Abstract][Full Text] [Related]
17. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
18. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products.
Charytan C; Schwenk MH; Al-Saloum MM; Spinowitz BS
Nephron Clin Pract; 2004; 96(2):c63-6. PubMed ID: 14988600
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
20. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients.
Airy M; Mandayam S; Mitani AA; Chang TI; Ding VY; Brookhart MA; Goldstein BA; Winkelmayer WC
Nephrol Dial Transplant; 2015 Dec; 30(12):2068-75. PubMed ID: 26311216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]